The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis

被引:4
|
作者
Li, Xiaoyan [1 ]
He, Jie [2 ,3 ]
Sun, Qiuhua [1 ]
机构
[1] Zhejiang Chinese Med Univ, Sch Nursing, 548 Binwen Rd, Hangzhou 310000, Zhejiang, Peoples R China
[2] Chengdu Med Coll, Affiliated Hosp 1, Dept Pulm & Crit Care Med, Chengdu 610500, Sichuan, Peoples R China
[3] Chengdu Med Coll, Clin Med Coll, Chengdu 610500, Sichuan, Peoples R China
关键词
Sarcopenia; Metabolic dysfunction-associated steatotic; liver disease (MASLD); Prevalence; Systematic review; Meta-analysis; INSULIN-RESISTANCE; FIBROSIS; NAFLD; RISK; STEATOHEPATITIS; QUALITY;
D O I
10.1016/j.clnu.2024.07.006
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background and aims: Sarcopenia is a common complication in patients with metabolic dysfunctionassociated steatotic liver disease (MASLD). However, the prevalence and its impact on the survival of sarcopenia in patients with MASLD is unknown. In this study, we aimed to assess the prevalence and effects of sarcopenia in patients with MASLD. Methods: Systematic review and meta-analysis of full texts of relevant studies were searched from inception until June 12, 2024 in five databases (PubMed, Cochrane Library, Embase, Web of Science, and the China National Knowledge Infrastructure). Next, we assessed the prevalence of sarcopenia in MASLD, and calculated the ORs and HRs between sarcopenia and MASLD based on the adjusted data from individual studies. Statistical analyses were performed using Stata 11.0. Results: Of the 2984 records considered, 29 studies recruiting 63,330 patients were included. The pooled prevalence of sarcopenia in patients with MASLD was 23.5% overall (95% CI; 19.1%-27.9%, I2 = 99.6%), and was higher in Asian patients, male, cross-sectional studies, when BIA were employed to measure muscle mass, one criterion of diagnosis sarcopenia, MASLD was diagnosed employing MRI, and moderate-quality studies. Sarcopenia was associated with MASLD patients (adjusted odds ratio [aOR] 2.08, 95% CI 1.58 -2.74, I2 = 93.6%) with similar findings in subgroups stratified by age, study design, methods for measuring muscle mass, assessment method to detect sarcopenia, and study quality. The association between all-cause mortality further supports the association between sarcopenia and poor prognosis with MASLD (aHR 1.59, 95% CI 1.33-1.91, I2 = 0%). Conclusions: Sarcopenia was strongly associated with MASLD progression and was a risk factor not only for MASLD pathogenesis but was also markedly correlated with MASLD-associated mortality. (c) 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:2005 / 2016
页数:12
相关论文
共 50 条
  • [41] Assessing the efficacy of farnesoid X receptor agonists in the management of metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis Efficacy of Farnesoid X Receptor Agonists in Metabolic Dysfunction- associated Steatotic Liver Disease: Systematic Review and Meta-analysis
    Kumar, Jai
    Hasan, Misha
    Mohsin, Sana
    Alzaher, Mojtaba Hussain
    Nagar, Tripti
    Jamil, Adeena
    Ahmed, Ali
    Krishna, Vamsi Lavu
    Kumar, Sarwan
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2025, 49 (02)
  • [42] THERAPEUTIC HORIZONS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE( MASLD) & METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS( MASH): A SYSTEMATIC REVIEW OF CURRENT TREATMENT OPTION
    Moliya, Pratiksha
    Al-Obaidi, Hasan
    Patel, Pranav
    Patel, Raj
    Parikh, Charmy
    Joy, Melvin
    HEPATOLOGY, 2024, 80
  • [43] INSULIN RESISTANCE IS A PREDICTOR OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND MASLD-ASSOCIATED FIBROSIS
    Kim, David S.
    Ismail, Mohamed
    Abboud, Yazan
    Khan, Wajiha
    Le, Alexander
    Pyrsopoulos, Nikolaos T.
    Kim, Hyunseok
    Hajifathalian, Kaveh
    GASTROENTEROLOGY, 2024, 166 (05) : S1657 - S1657
  • [44] Quercetin: A Promising Candidate for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Markowska, Julia
    Kasprzak-Drozd, Kamila
    Nizinski, Przemyslaw
    Dragan, Magdalena
    Kondracka, Adrianna
    Gondek, Ewa
    Oniszczuk, Tomasz
    Oniszczuk, Anna
    MOLECULES, 2024, 29 (22):
  • [45] Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Elshaer, Amani
    Chascsa, David M. H.
    Lizaola-Mayo, Blanca C.
    LIFE-BASEL, 2024, 14 (07):
  • [46] Efficacy of fish oil supplementation on metabolic dysfunction-associated steatotic liver disease: a meta-analysis
    Zhou, Like
    Sun, Dongmei
    Bai, Houqiao
    FRONTIERS IN NUTRITION, 2025, 12
  • [47] Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies
    Chan, Kai En
    Ong, Elden Yen Hng
    Chung, Charlotte Hui
    Ong, Christen En Ya
    Koh, Benjamin
    Tan, Darren Jun Hao
    Lim, Wen Hui
    Yong, Jie Ning
    Xiao, Jieling
    Wong, Zhen Yu
    Syn, Nicholas
    Kaewdech, Apichat
    Teng, Margaret
    Wang, Jiong-Wei
    Chew, Nicholas
    Young, Dan Yock
    Know, Alfred
    Siddiqui, Mohammad Shadab
    Huang, Daniel Q.
    Tamaki, Nobuharu
    Wong, Vincent Wai-Sun
    Mantzoros, Christos S.
    Sanyal, Arun
    Noureddin, Mazen
    Ng, Cheng Han
    Muthiah, Mark
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (03) : 488 - 498
  • [48] EATING DISORDERS IN MEXICAN POPULATION WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
    Contreras, Ana D. Cano
    Alvarez, Hector Ricardo Ordaz
    Priego-Parra, Bryan Adrian
    Martinez-Perez, Genesis Patricia
    Reyes-Diaz, Sara A.
    Azamar, Pamela Duran
    Garcia-Carvajal, Mario J.
    Diaz-Crespo, Angel H.
    Vazquez-Cruz, Anette P.
    Hernandez, Tonatiu Castellanos
    Basurto, Jose Luis Vargas
    Dietlen, Federico B. Roesch
    Francisco, Maria D.
    Amieva-Balmori, Mercedes
    Remes-Troche, Jose Maria
    GASTROENTEROLOGY, 2024, 166 (05) : S1649 - S1650
  • [49] Evaluation of a Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Clinical Pharmacy Service
    Sallam, Sandy
    Ahmed, Aijaz
    Gu, Xin
    DIABETES, 2024, 73
  • [50] ALTERED GUT VIRAL ECOLOGY IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
    Nzabarushimana, Etienne
    Kim, Hanseul
    Jensen, Jordan
    Shen, Jiaxian
    Nelson, Paul
    Thompson, Kelsey N.
    Chan, Andrew T.
    Hayete, Boris
    Huttenhower, Curtis
    Nguyen, Long H.
    GASTROENTEROLOGY, 2024, 166 (05) : S1539 - S1540